Skip to main content
. 2019 Feb 4;2(1):e201900313. doi: 10.26508/lsa.201900313

Figure S3. Residual enzymatic activity in media or cell lysates containing sitagliptin, UAMC39, UAMC1110, or KYP-2047.

Figure S3.

(A–H) BMDMs were mock-treated or received 10 μM of sitagliptin (A, B), UAMC39 (C, D), UAMC1110 (E, F) or KYP-2047 (G, H) for 15 min. Cell lysates (A, C, E, G) and supernatants (B, D, F, H) were analysed for their level of DPPIV, DPPII, FAP, or PREP inhibition, respectively, as described in the Materials and Methods section.